• Jeffrey S Berger, Brian G Katona, W Schuyler Jones, Manesh R Patel, Lars Norgren, Iris Baumgartner, Juuso Blomster, Kenneth W Mahaffey, Peter Held, Marcus Millegård, Gretchen Heizer, Craig Reist, F Gerry Fowkes, and William R Hiatt.
• Divisions of Cardiology and Vascular Surgery, Departments of Medicine and Surgery, New York University School of Medicine, New York, NY. Electronic address: Jeffrey.Berger@nyumc.org.
• Am. Heart J. 2016 May 1; 175: 86-93.

BackgroundDespite overwhelming data demonstrating the efficacy of antiplatelet therapy in heart disease and stroke, data in peripheral artery disease (PAD) are less compelling. Aspirin has modest evidence supporting a reduction in cardiovascular events in patients with PAD, whereas clopidogrel monotherapy may be more effective in PAD. Ticagrelor, a potent, reversibly binding P2Y12 receptor antagonist, is beneficial in patients with acute coronary syndrome and prior myocardial infarction. The EUCLID trial is designed to address the need for effective antiplatelet therapy in PAD to decrease the risk of cardiovascular events.Study DesignEUCLID is a randomized, double-blind, parallel-group, multinational clinical trial designed to evaluate the efficacy and safety of ticagrelor compared with clopidogrel for the prevention of major adverse cardiovascular events in subjects with symptomatic PAD. Subjects with established PAD will be randomized in a 1:1 fashion to ticagrelor 90 mg twice daily or clopidogrel 75 mg daily. The primary end point is a composite of cardiovascular death, myocardial infarction, or ischemic stroke. Other end points address limb events including acute leg ischemia, need for revascularization, disease progression by ankle-brachial index, and quality of life. The primary safety objective is Thrombolysis in Myocardial Infarction-defined major bleeding. Recruitment began in December 2012 and was completed in March 2014; 13,887 patients were randomized. The trial will continue until at least 1,364 adjudicated primary end points occur.ConclusionsThe EUCLID study is investigating whether treatment with ticagrelor versus clopidogrel, given as antiplatelet monotherapy, will reduce the incidence of cardiovascular and limb-specific events in patients with symptomatic PAD.Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

30 keywords...

hide…